Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2016 - 2022)

Intellia Therapeutics (NTLA) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $24.0 million as the latest value for Q4 2022.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $24.0 million in Q4 2022 year-over-year; TTM through Dec 2022 was $24.0 million, a N/A change, with the full-year FY2022 number at $24.0 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $24.0 million for Q4 2022 at Intellia Therapeutics, up from $18.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $24.0 million in Q4 2022 to a low of $13000.0 in Q4 2018.